PP69
β-Amyloid Peptide (1-42), Human
別名:
β-Amyloid Peptide (1-42), Human, DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式（ヒル表記法）:
C203H312N56O59S
分子量:
4513.05
NACRES:
NA.77
UNSPSC Code:
12352202
assay
≥95% (HPLC)
Quality Segment
form
lyophilized
does not contain
preservative
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, desiccated (hygroscopic)
dilution
(Substrate Cleavage Assays (30-100 μg/mL))
solubility
50 mM Tris-HCl, pH >9.0: ≤1 mg/mL
shipped in
ambient
storage temp.
−20°C
General description
Wild-type, human Aβ1-42 peptide. A number of mutations, identified in the gene encoding the β-amyloid precursor protein (βAPP), have been linked to early-onset Familial Alzheimer’s Disease. Mutations in the genes encoding presenilin 1 and presenilin 2 have also been shown to alter the processing of βAPP, resulting in increased extracellular concentration of β-amyloid peptide Aβ1-42(43) relative to Aβ1-40. Biophysical and biochemical experiments suggest that Aβ1-42(43) may serve as a catalyst for the aggregation and deposition of β-amyloid peptide (Aβ) leading to neurotoxic effects associated with senile plaque formation. Furthermore, antibodies recog-nizing Aβ1-42 revealed that the long form of the peptide is increased in presenilin and βAPP mutants, while other studies have used Aβ specific antibodies to prevent the in vitro fibrillar aggregation of Aβ. Amino acid sequence verified by amino acid analysis or sequencing. This product is supplied in a form that is not neurotoxic prior to a preincubation step. The appearance of toxicity has recently been shown to correlate to the extent of β sheet structure. Useful for neurotoxicity studies and substrate cleavage assays.
Immunogen
Human
Application
Substrate Cleavage Assays (30-100 μg/ml)
Physical form
Supplied as a chloride salt.
Preparation Note
Reconstitute just prior to use. Do not store following reconstitution, as aggregation may occur.
Other Notes
Citron, M., et al. 1997. Nature Med.3, 67.
Hardy, J. 1997. Trends in Neurosci.20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron13, 45.
Suzuki, N., et al. 1994. Science264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol.45, 373.
Hardy, J. 1997. Trends in Neurosci.20, 154.
Solomon, B., et al. 1997. Proc. Natl. Acad. Sci. USA94, 4109.
Duff, K., et al. 1996. Nature 383, 710.
Iwatsubo, T., et al. 1994. Neuron13, 45.
Suzuki, N., et al. 1994. Science264, 133.
Simmons, L.K., et al. 1994. Mol. Pharmacol.45, 373.
H-Asp-Ala-Glu-Phe-Arg-His-Asp-Ser-Gly-Tyr-Glu-Val-His-His-Gln-Lys-Leu-Val-Phe-Phe-Ala-Glu-Asp-Val-Gly-Ser-Asn-Lys-Gly-Ala-Ile-Ile-Gly-Leu-Met-Val-Gly-Gly-Val-Val-Ile-Ala-OH
Synthetic peptide corresponding to amino acid residues 1 - 42 of the processed human β-amyloid peptide.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable